top of page
Screen Shot 2019-04-01 at 12.50.10


Poly-ICLC, a multi-functional immune modulator for treating cancer
Sultan H, Celis E, Salazar A. (Seminars in Immunology, Jun 2020)
Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.
Sultan H, Celis E et al. (Journal for Immunotherapy in Cancer, Sept 2020)
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S, Okada H et al. (Journal of Clinical Investigation, Aug 2020)
Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Mode
Tran T, Jung T et al. (Frontiers in Immunology, Jun 2020)
Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L, Lasarte JJ (Journal for Immunotherapy in Cancer, Jun 2020)
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
Engelhard V, Slingluff C et al. (Journal for Immunotherapy in Cancer, May 2020)
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Najano, H et al. (Cancer Immunology, Immunotherapy, Mar 2020)
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Pavlick A, Bhardwaj N et al. (Cancer Immunology Research, Jan 2020)
The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
Weed D, Serafini P et al. (Frontiers in Immunology 2019)
Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.
Vivas I, Lasarte JJ et al. (Journal of Vacular and Interventional Radiology 2019)
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Saxena M, Miller E et al. (Frontiers in Immunology 2019)
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.
Boydell E, Dutoit V et al. (Cancers 2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
Hammerich L, Brody J et al. (Nature Medicine 2019)
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. 
Migliorini D, Dietrich, PY et al. (Neuro-oncology 2019)
The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice  
Sultan H, Celis E et al. (Cancer Immunology, Immunotherapy 2018)
The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys. 
Kende M, Salazar A et al. (Anitviral Research 2018)
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Wick W et al. (Nature  2019)
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
Smith M, Galuzzi L et al. (Oncoimmunology 2018)
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.
Flamar A, Levy Y et al. (PLoS One 2018)
Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma.
Tan L, Lim C et al. (Oncoimmunology 2018)

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Kyi C, Bhardwaj N et al. (Clinical Cancer Research; 2018)

Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.

Sultan H, Celis E et al. (Cancer Immunology, Immunotherapy; 2018)


An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott P, Wu C et al. (Nature 2017)

A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect

de la Torre A, Salazar A et al. (Journal of Hepatocellular Carcinoma; 2017)

Designing therapeutic cancer vaccines by mimicking viral infections.

Sultan H, Celis E et al. (Cancer Immunotherpy; 2017)

Cytosolic Receptor Melanoma Differentiation–Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury

Gesuete R, Stenzel-Poore M et al. (Stroke; 2016)

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.

Salazar A, Herberman R et al. (Cancer Immunology Research; 2014)

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Kimura T, Finn O et al. (Cancer Prevention Research; 2013)

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinicalactivity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Okada H, Lieberman F et al. (Journal of Clinical Oncology; 2011)

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccinein humans.

Caskey M, Sekaly R, Steinman R et al. (The Journal of Experimental Medicine 2011) 

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.

Rosenfeld M, Ye X et al. (Neuro-oncology 2010)

Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.

Salazar A, Omaya A et al. (Neurosurgery 1996)

bottom of page